Cholinergic activity as a new target in diseases of the heart

Molecular Medicine

Volumn 20, Issue JULY-DECEMBER 2014, 2014, Pages 527-537

  Roy, Ashbeel ^a,b   Guatimosim, Silvia ^c   Prado, Vania F ^a,b   Gros, Robert ^a,b   Prado, Marco A M ^a,b  

^a ROBARTS RESEARCH INSTITUTE   (Canada)

^b UNIVERSITY OF WESTERN ONTARIO   (Canada)

^c FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCHOLINE; CHOLINE; PYRIDOSTIGMINE; CHOLINESTERASE INHIBITOR;

ACETYLCHOLINE RELEASE; ARTICLE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RESPONSE; CARDITIS; CHOLINERGIC ACTIVITY; CHOLINERGIC TRANSMISSION; CHOLINESTERASE INHIBITION; DRUG MECHANISM; DRUG RESPONSE; DRUG TARGETING; HEART DISEASE; HEART FAILURE; HUMAN; MORBIDITY; NONHUMAN; PARASYMPATHETIC TONE; PATHOGENESIS; SIGNAL TRANSDUCTION; SYMPATHETIC TONE; TREATMENT OUTCOME; VAGUS NERVE; VAGUS NERVE STIMULATION; ANIMAL; AUTONOMIC NERVOUS SYSTEM; HEART DISEASES; METABOLISM;

ACETYLCHOLINE; ANIMALS; AUTONOMIC NERVOUS SYSTEM; CHOLINESTERASE INHIBITORS; HEART DISEASES; HUMANS;

EID: 84921932425     PISSN: 10761551     EISSN: 15283658     Source Type: Journal    
DOI: 10.2119/molmed.2014.00125     Document Type: Article

References (147)

1. Wessler I, Kirkpatrick CJ, Racke K. (1999) The cholinergic 'pitfall': acetylcholine, a universal cell molecule in biological systems, including humans. Clin. Exp. Pharmacol. Physiol 26:198-205.
2. Nachmansohn D, Machado AL. (1943) The formation of acetylcholine: a new enzyme: choline acetylase. J. Neurophysiol 6:397-403.
3. Brandon EP, et al. (2004) Choline transporter 1 maintains cholinergic function in choline acetyltrans-ferase haploinsufficiency. J. Neurosci. 24:5459-66.
4. Okuda T, Haga T. (2003) High-affinity choline transporter. Neurochem. Res. 28:483-8.
5. Kuhar MJ, Murrin LC. (1978) Sodium-dependent, high affinity choline uptake. J. Neurochem. 30:15-21.
6. Ferguson SM, et al. (2004) Lethal impairment of cholinergic neurotransmission in hemicholinium-3-sensitive choline transporter knockout mice. Proc. Natl. Acad. U. S. A. 101:8762-7.
7. Erickson JD, et al. (1994) Functional identification of a vesicular acetylcholine transporter and its expression from a "cholinergic" gene locus. J. Biol. Chem. 269:21929-32.
8. de Castro BM, et al. (2009) The vesicular acetylcholine transporter is required for neuromuscu-lar development and function. Mol. Cell. Biol. 29:5238-50.
9. Prado VF, et al. (2006) Mice deficient for the vesicular acetylcholine transporter are myasthenic and have deficits in object and social recognition. Neuron. 51:601-12.
10. Song H, et al. (1997) Expression of a putative vesicular acetylcholine transporter facilitates quantal transmitter packaging. Neuron. 18:815-26.
11. Kolisnyk B, et al. (2013) ChAT-ChR2-EYFP mice have enhanced motor endurance but show deficits in attention and several additional cognitive domains. J. Neurosci. 33:10427-38.
12. Nagy PM, Aubert I. (2012) Overexpression of the vesicular acetylcholine transporter increased acetylcholine release in the hippocampus. Neuroscience. 218:1-11.
13. Kent KM, Epstein SE, Cooper T, Jacobowitz DM. (1974) Cholinergic innervation of the canine and human ventricular conducting system: anatomic and electrophysiologic correlations. Circulation. 50:948-55.
14. Brodde OE, Bruck H, Leineweber K, Seyfarth T. (2001) Presence, distribution and physiological function of adrenergic and muscarinic receptor subtypes in the human heart. Basic Res. Cardiol. 96:528-38.
15. Agostoni E, Chinnock JE, De Daly MB, Murray JG. (1957) Functional and histological studies of the vagus nerve and its branches to the heart, lungs and abdominal viscera in the cat. J. Physiol. 135:182-205.
16. Sunahara RK, Dessauer CW, Gilman AG. (1996) Complexity and diversity of mammalian adenylyl cyclases. Ann. Rev. Pharmacol. Toxicol. 36:461-80.
17. Ishikawa Y, Homcy CJ. (1997) The adenylyl cy-clases as integrators of transmembrane signal transduction. Circ. Res. 80:297-304.
18. Osterrieder W, et al. (1982) Injection of subunits of cyclic AMP-dependent protein kinase into cardiac myocytes modulates Ca2+ current. Nature. 298:576-8.
19. Logothetis DE, Kurachi Y, Galper J, Neer EJ, Clapham DE. (1987) The beta gamma subunits of GTP-binding proteins activate the muscarinic K+ channel in heart. Nature. 325:321-6.
20. DiFrancesco D, Ducouret P, Robinson RB. (1989) Muscarinic modulation of cardiac rate at low acetylcholine concentrations. Science. 243:669-71.
21. DiFrancesco D, Tromba C. (1987) Acetylcholine inhibits activation of the cardiac hyperpolarizing-activated current, if. Pflugers Arch. 410:139-42.
22. Peralta EG, et al. (1987) Distinct primary structures, ligand-binding properties and tissue-specific expression of four human muscarinic acetyl- choline receptors. EMBO J. 6:3923-9.
23. Caulfield MP. (1993) Muscarinic receptors: characterization, coupling and function. Pharmacol. Ther. 58:319-79.
24. Ponicke K, Heinroth-Hoffmann I, Brodde OE. (2003) Demonstration of functional M3-mus-carinic receptors in ventricular cardiomyocytes of adult rats. Br. J. Pharmacol. 138:156-60.
25. Nishimaru K, Tanaka Y, Tanaka H, Shigenobu K. (2000) Positive and negative inotropic effects of muscarinic receptor stimulation in mouse left atria. Life Sci. 66:607-15.
26. Pan Z, et al. (2012) M3 subtype of muscarinic acetyl-choline receptor promotes cardioprotection via the suppression of miR-376b-5p. PloS One. 7:e32571.
27. Liu Y, et al. (2013) Upregulation of M(3) mus-carinic receptor inhibits cardiac hypertrophy induced by angiotensin II. J. Transl. Med. 11:209.
28. Chiappinelli VA, Dryer SE. (1984) Nicotinic transmission in sympathetic ganglia: blockade by the snake venom neurotoxin kappa-bungaro-toxin. Neurosci. Lett. 50:239-44.
29. Galvan M. (1988) Modulation of synaptic transmission in autonomic ganglia mediated via the activation of postganglionic muscarinic M1 receptors. Pharmacology. 37 (Suppl. 1):11-6.
30. Habermeier-Muth A, Altes U, Forsyth KM, Muscholl E. (1990) A presynaptic excitatory M1 muscarine receptor at postganglionic cardiac no-radrenergic nerve fibres that is activated by endogenous acetylcholine. Naunyn-Schmiedebergs Arch. Pharmacol. 342:483-9.
31. Trendelenburg AU, Gomeza J, Klebroff W, Zhou H, Wess J. (2003) Heterogeneity of presynaptic mus-carinic receptors mediating inhibition of sympathetic transmitter release: a study with M2- and M4-receptor-deficient mice. Br. J. Pharmacol. 138:469-80.
32. Liu HR, Zhao RR, Jiao XY, Wang YY, Fu M. (2002) Relationship of myocardial remodeling to the genesis of serum autoantibodies to cardiac beta(1)-adrenoceptors and muscarinic type 2 acetylcholine receptors in rats. J. Am. Coll. Cardiol. 39:1866-73.
33. Hollinger S, Hepler JR. (2002) Cellular regulation of RGS proteins: modulators and integrators of G protein signaling. Pharmacol. Rev. 54:527-59.
34. Heximer SP, Watson N, Linder ME, Blumer KJ, Hepler JR. (1997) RGS2/G0S8 is a selective inhibitor of Gqalpha function. Proc. Natl. Acad. U. S. A. 94:14389-93.
35. Chidiac P, Ross EM. (1999) Phospholipase C- beta1 directly accelerates GTP hydrolysis by Gal-phaq and acceleration is inhibited by Gbeta gamma subunits. J. Biol. Chem. 274:19639-43.
36. Heximer SP, et al. (1999) G protein selectivity is a determinant of RGS2 function. J. Biol. Chem. 274:34253-9.
37. Cladman W, Chidiac P. (2002) Characterization and comparison of RGS2 and RGS4 as GTPase-activating proteins for m2 muscarinic receptor-stimulated G(i). Mol. Pharmacol. 62:654-9.
38. Roy AA, et al. (2006) Up-regulation of endogenous RGS2 mediates cross-desensitization between Gs and Gq signaling in osteoblasts. J. Biol. Chem. 281:32684-93.
39. Nunn C, et al. (2010) RGS2 inhibits beta-adrenergic receptor-induced cardiomyocyte hypertrophy. Cell. Sig. 22:1231-9.
40. Chidiac P, Sobiesiak AJ, Lee KN, Gros R, Nguyen CH. (2014) The eIF2B-interacting domain of RGS2 protects against GPCR agonist-induced hypertrophy in neonatal rat cardiomyocytes. Cell. Sig. 26:1226-1234.
41. Heximer SP, et al. (2003) Hypertension and prolonged vasoconstrictor signaling in RGS2-deficient mice. J. Clin. Invest. 111:445-52.
42. Takimoto E, et al. (2009) Regulator of G protein signaling 2 mediates cardiac compensation to pressure overload and antihypertrophic effects of PDE5 inhibition in mice. J. Clin. Invest. 119:408-20.
43. Just A, Faulhaber J, Ehmke H. (2000) Autonomic cardiovascular control in conscious mice. Am. J. Physiol. 279:R2214-21.
44. Olshansky B, Sabbah HN, Hauptman PJ, Colucci WS. (2008) Parasympathetic nervous system and heart failure: pathophysiology and potential implications for therapy. Circulation. 118:863-71.
45. Go AS, et al. (2014) Heart disease and stroke statistics: 2014 update: a report from the American Heart Association. Circulation. 129:e28-e292.
46. Mann DL. (1999) Mechanisms and models in heart failure: a combinatorial approach. Circulation. 100:999-1008.
47. Braunwald E, Bristow MR. (2000) Congestive heart failure: fifty years of progress. Circulation. 102:IV14-23.
48. Floras JS. (2009) Sympathetic nervous system activation in human heart failure: clinical implications of an updated model. J. Am. Coll. Cardiol. 54:375-85.
49. Massie BM. (1988) Is neurohormonal activation deleterious to the long-term outcome of patients with congestive heart failure? I. Introduction. J. Am. Coll. Cardiol. 12:547-550.
50. Grassi G, et al. (2001) Sympathetic and reflex abnormalities in heart failure secondary to is-chaemic or idiopathic dilated cardiomyopathy. Clin. Sci. (Lond). 101:141-6.
51. Grassi G, et al. (1995) Sympathetic activation and loss of reflex sympathetic control in mild congestive heart failure. Circulation. 92:3206-11.
52. Rockman HA, Koch WJ, Lefkowitz RJ. (2002) Seven-transmembrane-spanning receptors and heart function. Nature. 415:206-12.
53. DiPiro JT, et al. (2008) Pharmacotherapy: A Pathophysiological Approach. 7th ed. New York: McGraw-Hill Medical. 2559 pp.
54. Triposkiadis F, et al. (2009) The sympathetic nervous system in heart failure physiology, pathophysiology, and clinical implications. J. Am. Coll. Cardiol. 54:1747-62.
55. Grassi G, et al. (2009) Sympathetic and baroreflex cardiovascular control in hypertension-related left ventricular dysfunction. Hypertension. 53:205-9.
56. Zucker IH, et al. (2007) Chronic baroreceptor activation enhances survival in dogs with pacing-induced heart failure. Hypertension. 50:904-10.
57. Yancy CW, et al. (2013) 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/ American Heart Association Task Force on Practice Guidelines. J. Am. Coll. Cardiol. 62:e147-239.
58. Hjalmarson A, et al. (1999) Effect of metoprolol CR XL in chronic heart failure: Metoprolol CR XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet. 353:2001-7.
59. Poole-Wilson PA, et al. (2003) Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol, European Trial (COMET): randomised controlled trial. Lancet. 362:7-13.
60. Wollert KC, Drexler H. (2002) Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) trial: carvedilol as the sun and center of the beta-blocker world? Circulation. 106:2164-66.
61. Iwata M, et al. (2001) Autoantibodies against the second extracellular loop of beta1-adrenergic receptors predict ventricular tachycardia and sudden death in patients with idiopathic dilated car-diomyopathy. J. Am. Coll. Cardiol. 37:418-24.
62. Peukert S, et al. (1999) The frequency of occurrence of anti-cardiac receptor autoantibodies and their correlation with clinical manifestation in patients with hypertrophic cardiomyopathy. Au-toimmunity. 29:291-7.
63. Magnusson Y, Wallukat G, Waagstein F, Hjalmarson A, Hoebeke J. (1994) Autoimmunity in idiopathic dilated cardiomyopathy: characterization of antibodies against the beta(1)-adrenoceptor with positive chronotropic effect. Circulation. 89:2760-7.
64. Davies JE, et al. (2013) First-in-man safety evaluation of renal denervation for chronic systolic heart failure: primary outcome from REACH- Pilot study. Int. J. Cardiol. 162:189-92.
65. Brandt MC, et al. (2012) Renal sympathetic dener-vation reduces left ventricular hypertrophy and improves cardiac function in patients with resistant hypertension. J. Am. Coll. Cardiol. 59:901-9.
66. Linz D, et al. (2012) Renal sympathetic denerva-tion suppresses postapneic blood pressure rises and atrial fibrillation in a model for sleep apnea. Hypertension. 60:172-8.
67. Ukena C, et al. (2013) Effects of renal sympathetic denervation on heart rate and atrioventricular conduction in patients with resistant hypertension. Int. J. Cardiol. 167:2846-51.
68. Binkley PF, Nunziata E, Haas GJ, Nelson SD, Cody RJ. (1991) Parasympathetic withdrawal is an integral component of autonomic imbalance in congestive heart failure: demonstration in human subjects and verification in a paced canine model of ventricular failure. J. Am. Coll. Car-diol. 18:464-72.
69. Vanoli E, et al. (1991) Vagal stimulation and prevention of sudden death in conscious dogs with a healed myocardial infarction. Circ. Res. 68:1471-81.
70. Billman GE, Schwartz PJ, Stone HL. (1982) Barore-ceptor reflex control of heart rate: a predictor of sudden cardiac death. Circulation. 66:874-80.
71. Fu LX, et al. (1993) Localization of a functional autoimmune epitope on the muscarinic acetyl-choline receptor-2 in patients with idiopathic dilated cardiomyopathy. J. Clin. Invest. 91:1964-8.
72. Kinugawa T, Dibner-Dunlap ME. (1995) Altered vagal and sympathetic control of heart rate in left ventricular dysfunction and heart failure. Am. J. Physiol. 268:R310-6.
73. Bibevski S, Dunlap ME. (1999) Ganglionic mechanisms contribute to diminished vagal control in heart failure. Circulation. 99:2958-63.
74. Schwartz PJ, De Ferrari GM. (2011) Sympathetic- parasympathetic interaction in health and disease: abnormalities and relevance in heart failure. Heart Fail. Rev. 16:101-7.
75. LaCroix C, Freeling J, Giles A, Wess J, Li YF. (2008) Deficiency of M2 muscarinic acetylcholine receptors increases susceptibility of ventricular function to chronic adrenergic stress. Am. J. Phys-iol. 294:H810-20.
76. Martos R, et al. (2007) Diastolic heart failure: evidence of increased myocardial collagen turnover linked to diastolic dysfunction. Circulation. 115:888-895.
77. Yan AT, et al. (2006) Plasma matrix metallopro-teinase-9 level is correlated with left ventricular volumes and ejection fraction in patients with heart failure. J. Card. Fail. 12:514-9.
78. Lara A, et al. (2010) Dysautonomia due to reduced cholinergic neurotransmission causes cardiac remodeling and heart failure. Mol. Cell. Biol. 30:1746-56.
79. Roy A, et al. (2012) An analysis of the myocardial transcriptome in a mouse model of cardiac dysfunction with decreased cholinergic neurotransmission. PLoS One. 7:e39997.
80. English BA, et al. (2010) Tachycardia, reduced vagal capacity, and age-dependent ventricular dysfunction arising from diminished expression of the presynaptic choline transporter. Am. J. Physiol. Heart Circ. Physiol. 299:H799-810.
81. Mesulam MM, et al. (2002) Acetylcholinesterase knockouts establish central cholinergic pathways and can use butyrylcholinesterase to hydrolyze acetylcholine. Neuroscience. 110:627-39.
82. Chatonnet A, Lockridge O. (1989) Comparison of butyrylcholinesterase and acetylcholinesterase. Biochem. J. 260:625-34.
83. Li B, et al. (2000) Abundant tissue butyrylcholines-terase and its possible function in the acetylcholines-terase knockout mouse. J. Neurochem. 75:1320-31.
84. Calderon-Margalit R, Adler B, Abramson JH, Gofin J, Kark JD. (2006) Butyrylcholinesterase ac- tivity, cardiovascular risk factors, and mortality in middle-aged and elderly men and women in Jerusalem. Clin. Chem. 52:845-52.
85. Goliasch G, et al. (2012) Butyrylcholinesterase activity predicts long-term survival in patients with coronary artery disease. Clin. Chem. 58:1055-8.
86. Goliasch G, et al. (2012) Routinely available bio-markers improve prediction of long-term mortality in stable coronary artery disease: the Vienna and Ludwigshafen Coronary Artery Disease (VILCAD) risk score. Eur. Heart J. 33:2282-9.
87. Li M, et al. (2004) Vagal nerve stimulation markedly improves long-term survival after chronic heart failure in rats. Circulation. 109:120-4.
88. Zhang Y, et al. (2009) Chronic vagus nerve stimulation improves autonomic control and attenuates systemic inflammation and heart failure progression in a canine high-rate pacing model. Circ. Heart Fail. 2:692-9.
89. Handa T, et al. (2009) Anti-Alzheimer's drug, donepezil, markedly improves long-term survival after chronic heart failure in mice. J. Card. Fail. 15:805-11.
90. Li M, et al. (2013) Donepezil markedly improves long-term survival in rats with chronic heart failure after extensive myocardial infarction. Circ. J. 77:2519-25.
91. Lataro RM, et al. (2013) Increase in parasympa-thetic tone by pyridostigmine prevents ventricular dysfunction during the onset of heart failure. Am. J. Physiol. 305:R908-16.
92. Gavioli M, et al. (2014) Cholinergic signaling exerts protective effects in models of sympathetic hyperactivity-induced cardiac dysfunction. PLoS One. 9:e100179.
93. Behling A, et al. (2003) Cholinergic stimulation with pyridostigmine reduces ventricular arrhythmia and enhances heart rate variability in heart failure. Am. Heart J. 146:494-500.
94. Androne AS, Hryniewicz K, Goldsmith R, Arwady A, Katz SD. (2003) Acetylcholinesterase inhibition with pyridostigmine improves heart rate recovery after maximal exercise in patients with chronic heart failure. Heart. 89:854-8.
95. Serra SM, Costa RV, Teixeira De Castro RR, Xavier SS, Nobrega AC. (2009) Cholinergic stimulation improves autonomic and hemodynamic profile during dynamic exercise in patients with heart failure. J. Card. Fail. 15:124-9.
96. Schwartz PJ, et al. (2008) Long term vagal stimulation in patients with advanced heart failure: first experience in man. Eur. J. Heart Fail. 10:884-91.
97. De Ferrari GM, et al. (2011) Chronic vagus nerve stimulation: a new and promising therapeutic approach for chronic heart failure. Eur. Heart J. 32:847-55.
98. Nordstrom P, Religa D, Wimo A, Winblad B, Eriksdotter M. (2013) The use of cholinesterase inhibitors and the risk of myocardial infarction and death: a nationwide cohort study in subjects with Alzheimer's disease. Eur. Heart J. 34:2585-91.
99. Friedman A, et al. (1996) Pyridostigmine brain penetration under stress enhances neuronal excitability and induces early immediate tran-scriptional response. Nat. Med. 2:1382-5.
100. Dillman JF 3rd, et al. (2009) Gene expression profiling of rat hippocampus following exposure to the acetylcholinesterase inhibitor soman. Chem. Res. Toxicol. 22:633-8.
101. Zhao Y, et al. (2013) Choline protects against cardiac hypertrophy induced by increased afterload. Int. J. Biol. Sci. 9:295-302.
102. Wang S, et al. (2012) Choline inhibits angiotensin II-induced cardiac hypertrophy by intracellular calcium signal and p38 MAPK pathway. Naunyn-Schmiedebergs Arch. Pharmacol. 385:823-31.
103. Kanazawa H, et al. (2010) Heart failure causes cholinergic transdifferentiation of cardiac sympathetic nerves via gp130-signaling cytokines in rodents. J. Clin. Invest. 120:408-21.
104. Grando SA, Kist DA, Qi M, Dahl MV. (1993) Human keratinocytes synthesize, secrete, and degrade acetylcholine. J. Invest. Dermatol. 101:32-6.
105. Reinheimer T, et al. (1998) Glucocorticoids mediate reduction of epithelial acetylcholine content in the airways of rats and humans. Euro. J. Pharmacol. 349:277-84.
106. Nguyen VT, et al. (2000) Choline acetyltransferase, acetylcholinesterase, and nicotinic acetylcholine receptors of human gingival and esophageal epithelia. J. Dent. Res. 79:939-49.
107. Maeda S, et al. (2011) Non-neuronal expression of choline acetyltransferase in the rat kidney. Life Sci. 89:408-14.
108. Rodriguez-Diaz R, et al. (2011) Alpha cells secrete acetylcholine as a non-neuronal paracrine signal priming beta cell function in humans. Nat. Med. 17:888-92.
109. Rosas-Ballina M, et al. (2011) Acetylcholine-syn-thesizing T cells relay neural signals in a vagus nerve circuit. Science. 334:98-101.
110. Fujii T, et al. (1996) Localization and synthesis of acetylcholine in human leukemic T cell lines. J. Neurosci. Res. 44:66-72.
111. Hoover DB, Ganote CE, Ferguson SM, Blakely RD, Parsons RL. (2004) Localization of choliner-gic innervation in guinea pig heart by immuno-histochemistry for high-affinity choline transporters. Cardiovasc. Res 62:112-21.
112. Crick SJ, et al. (1994) Innervation of the human cardiac conduction system: a quantitative im-munohistochemical and histochemical study. Circulation. 89:1697-708.
113. Gatti PJ, et al. (1997) Vagal control of left ventricular contractility is selectively mediated by a cranioventricular intracardiac ganglion in the cat. J. Auton. Nerv. Syst. 66:138-44.
114. Nakano H, et al. (1998) Right ventricular responses to vagus stimulation of fibers to discrete cardiac regions in dog hearts. J. Auton. Nerv. Syst. 74:179-88.
115. Lewis ME, et al. (2001) Vagus nerve stimulation decreases left ventricular contractility in vivo in the human and pig heart. J. Physiol. 534:547-52.
116. Rysevaite K, et al. (2011) Immunohistochemical characterization of the intrinsic cardiac neural plexus in whole-mount mouse heart preparations. Heart Rhythm. 8:731-8.
117. Zang WJ, Chen LN, Yu XJ. (2005) Progress in the study of vagal control of cardiac ventricles. Sheng Li Xue Bao. 57:659-72.
118. Kawano H, Okada R, Yano K. (2003) Histological study on the distribution of autonomic nerves in the human heart. Heart Vessels. 18:32-9.
119. Rana OR, et al. (2010) Acetylcholine as an age-dependent non-neuronal source in the heart. Auton. Neurosci. 156:82-9.
120. Kakinuma Y, Akiyama T, Sato T. (2009) Cholinocep-tive and cholinergic properties of cardiomyocytes involving an amplification mechanism for vagal efferent effects in sparsely innervated ventricular myocardium. FEBS J. 276:5111-25.
121. Kummer W, et al. (2006) Role of acetylcholine and polyspecific cation transporters in serotonin-induced bronchoconstriction in the mouse. Respir. Res. 7:65.
122. Lips KS, et al. (2005) Polyspecific cation transporters mediate luminal release of acetylcholine from bronchial epithelium. Am. J. Respir. Cell Mol. Biol. 33:79-88.
123. Wessler I, et al. (2001) Release of non-neuronal acetylcholine from the isolated human placenta is mediated by organic cation transporters. Br. J. Pharmacol. 134:951-6.
124. Bader S, Klein J, Diener M. (2014) Choline acetyltransferase and organic cation transporters are responsible for synthesis and propi-onate-induced release of acetylcholine in colon epithelium. Eur. J. Pharmacol. 733:23-33.
125. Rocha-Resende C, et al. (2012) Non-neuronal cholinergic machinery present in cardiomy-ocytes offsets hypertrophic signals. J. Mol. Cell. Cardiol. 53:206-16.
126. Roy A, et al. (2013) Cardiomyocyte-secreted acetylcholine is required for maintenance of ho- meostasis in the heart. FASEB J. 27:5072-82.
127. Kakinuma Y, et al. (2012) A non-neuronal cardiac cholinergic system plays a protective role in myocardium salvage during ischemic insults. PLoS One. 7:e50761.
128. Kakinuma Y, et al. (2013) Heart-specific overexpression of choline acetyltransferase gene protects murine heart against ischemia through hy-poxia-inducible factor-1alpha-related defense mechanisms. J. Am. Heart Assoc. 2:e004887.
129. Rinner I, Schauenstein K. (1993) Detection of choline-acetyltransferase activity in lymphocytes. J. Neurosci. Res. 35:188-91.
130. Tracey KJ. (2002) The inflammatory reflex. Nature. 420:853-9.
131. Wang H, et al. (2003) Nicotinic acetylcholine receptor alpha7 subunit is an essential regulator of inflammation. Nature. 421:384-8.
132. Bellinger DL, Lorton D, Hamill RW, Felten SY, Felten DL. (1993) Acetylcholinesterase staining and choline acetyltransferase activity in the young adult rat spleen: lack of evidence for cholinergic innervation. Brain Behav. Immun. 7:191-204.
133. Guarini S, et al. (2003) Efferent vagal fibre stimulation blunts nuclear factor-kappaB activation and protects against hypovolemic hemorrhagic shock. Circulation. 107:1189-94.
134. Shytle RD, et al. (2004) Cholinergic modulation of microglial activation by alpha 7 nicotinic receptors. J. Neurochem. 89:337-43.
135. Borovikova LV, et al. (2000) Vagus nerve stimulation attenuates the systemic inflammatory response to endotoxin. Nature. 405:458-62.
136. Chen JK, et al. (2012) Downregulation of alpha7 nicotinic acetylcholine receptor in two-kidney one-clip hypertensive rats. BMC Cardiovasc. Disord. 12:38.
137. Levine B, Kalman J, Mayer L, Fillit HM, Packer M. (1990) Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N. Engl. J. Med. 323:236-41.
138. Shan K, et al. (1997) The role of cytokines in disease progression in heart failure. Curr. Opin. Cardiol. 12:218-23.
139. Mann DL. (2002) Inflammatory mediators and the failing heart: past, present, and the foreseeable future. Circ. Res. 91:988-98.
140. Schulte A, Lichtenstern C, Henrich M, Weigand MA, Uhle F. (2014) Loss of vagal tone aggravates systemic inflammation and cardiac impairment in endotoxemic rats. J. Surg. Res. 188:480-8.
141. Li DJ, et al. (2011) Dysfunction of the cholinergic anti-inflammatory pathway mediates organ damage in hypertension. Hypertension. 57:298-307.
142. Aukrust P, et al. (1998) Elevated circulating levels of C-C chemokines in patients with congestive heart failure. Circulation. 97:1136-43.
143. Kubota T, et al. (1997) Dilated cardiomyopathy in transgenic mice with cardiac-specific overexpression of tumor necrosis factor-alpha. Circ. Res. 81:627-35.
144. Martelli D, Yao ST, McKinley MJ, McAllen RM. (2014) Reflex control of inflammation by sympathetic nerves, not the vagus. J. Physiol. 592:1677-86.
145. Bratton BO, et al. (2012) Neural regulation of inflammation: no neural connection from the vagus to splenic sympathetic neurons. Exp. Physiol. 97:1180-5.
146. Borovikova LV, et al. (2000) Role of vagus nerve signaling in CNI-1493-mediated suppression of acute inflammation. Auton. Neurosci. 85:141-7.
147. Collins FS. (2011) Mining for therapeutic gold. Nat. Rev. Drug Discov. 10:397.